Resource Availability
@ American Psychiatric Association. All rights reserved. This course material was originally created for SMI Adviser, and is now utilized with permission for the APAF SMI Learning Resource Center. The content in this course material is still current and relevant, yet, please be aware that some external resources and links may no longer be active or available.
Description
The webinar will provide an overview of current professional practice guidelines and scientific publications on long-acting injectable antipsychotics use in treatment of schizophrenia. Many patients diagnosed with schizophrenia who are eligible for treatment LAI antipsychotics are limited in access to this treatment modality because of clinicians limited on advantages of LAIs over oral antipsychotics. Learners need to understand how utilization of LAIs in evidence-based prescribing can improve patient outcomes and decrease health care cost in treatment of patients with schizophrenia. This activity provides information on the professional guidelines on use of LAIs in treatment of patients with schizophrenia and specific advantages of selecting evidence-based treatment to improve patient outcomes.
This course material was developed by SMI Adviser. Please be aware that some external resources and links referenced within this material may no longer be active or available.
Format
Recorded webinar
Learning Objectives
- Review the American Psychiatric Association statements on utilizing LAIs in treatment of patients with schizophrenia.
- Examine key findings in the peer-reviewed publications on oral vs. long-acting injectable antipsychotic use in patients with schizophrenia.
- Contrast research findings on the first- and second-generation long-acting injectable antipsychotics.
Target Audience
Nurse/Nurse Practitioner, Pharmacist, Psychiatrist, Physician (Non-psychiatrist), Physician Assistant
Instructional Level
Introductory, Intermediate, Advanced
Estimate Time to Complete
Estimated Duration: 1.0 hour
Program Start Date: January 21, 2026
Program End Date: January 21, 2029
Certificate of Participation
After completing the evaluation, participants will have the opportunity to download a certificate of participation. No continuing education credits are provided for this activity.
Faculty and Planner Disclosures
Instructors
- Leon Ravin, MD has been the statewide psychiatric medical director in Nevada since August 2015, and previously served as an associate medical director. Since 2006, he has worked in clinical and administrative roles at Southern Nevada Adult Mental Health Services, including taking an active role in testifying on mental health laws and community standards of care before the Nevada Legislature. Dr. Ravin has been the director of graduate and postgraduate medical education for the state Division of Public and Behavioral Health since 2012 while also teaching as a clinical professor for the University of Nevada School of Medicine. Dr. Ravin serves as an expert for SMI Adviser’s Long-acting Injectable Center of Excellence. Dr. Ravin is a member of the Janssen Neuroscience Mood Speaker Bureau and has developed non-promotional content for PsychU on Psychiatric Advance Directives.
Planners
- Teri Brister, PhD, LPC, National Alliance on Mental Illness. Reports no financial relationships with commercial interests.
- John Torous, MD, Beth Israel Deaconess Medical Center. Reports no financial relationships with commercial interests.
- Donna Rolin, PhD, APRN, University of Texas at Austin. Reports no financial relationships with commercial interests.
Accessibility for Participants with Disabilities
The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. Please contact the American Psychiatric Association at 202-559-3900, if you require assistance seven (7) business days prior to the start of a live webinar.
Technical Requirements
This internet-based CME activity is best experienced using any of the following:
- The latest and 2nd latest public versions of Google Chrome, Mozilla Firefox, or Safari
This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Acrobat Reader, Microsoft PowerPoint, and Windows Media Player.
Optimal System Configuration:
- Browser: Google Chrome (latest and 2nd latest version), Safari (latest and 2nd latest version), Internet Explorer 11.0+, Firefox (latest and 2nd latest version), or Microsoft Edge (latest and 2nd latest version)
- Operating System: Windows versions 8.1+, Mac OS X 10.5 (Leopard) +, Android (latest and 2nd latest version), or iOS/iPad OS (latest and 2nd latest version)
- Internet Connection: 1 Mbps or higher
Minimum Requirements:
- Windows PC: Windows 8.1 or higher; 1 GB (for 32-bit)/2 GB (for 64-bit) or higher RAM; Microsoft DirectX 9 graphics device with WDDM driver; audio playback with speakers for programs with video content
- Macintosh: Mac OS X 10.5 or higher with latest updates installed; Intel, PowerPC G5, or PowerPC G4 (867MHz or faster) processor; 512 MB or higher RAM; audio playback with speakers for programs with video content
For assistance: Contact for questions about this activity |
Contact for technical assistance